AN ANTIBACTERIAL chewing gum has shown early promise against cancer-linked oral microbes, reducing HPV and harmful bacteria in patient samples while preserving healthy mouth flora, raising interest in a simple preventive tool for oral health.
Oral Bacteria
Head and neck squamous cell carcinoma has been linked with higher oral levels of human papilloma virus, Porphyromonas gingivalis, and Fusobacterium nucleatum. These microbes are associated with worse outcomes, recurrence, or transmission risk. Researchers therefore explored whether an antibacterial chewing gum could selectively lower harmful organisms without disrupting beneficial oral bacteria.
Clinical Testing of Antibacterial Chewing Gum
In this ex vivo clinical study, saliva and oral-rinse samples were collected from patients with head and neck squamous cell carcinoma. HPV ELISA testing detected viruses in 100% of saliva samples and 75% of oral-rinse samples (n=44). Cell culture studies found 1000-fold higher Pg and Fn in saliva and 100-fold higher levels in oral-rinse samples versus non-cancer controls. Investigators tested bean-lectin FRIL gum, which traps viral particles, and a bioengineered bean gum containing protegrin-1, an antimicrobial peptide.
Marked Reductions in Targeted Microbes
Bean gum extracts reduced HPV levels by 93% in saliva samples and by 80% in oral-rinse samples. A single dose of antibacterial chewing gum containing protegrin-1 reduced Pg and Fn by more than 99% in saliva and oral-rinse samples. Investigators reported levels fell to almost zero in tested specimens. Protegrin remained active against anaerobic Pg and Fn but did not kill capsule-forming bacteria including Streptococci, suggesting selective preservation of beneficial flora.
Potential Role in Prevention and Adjunct Care
These findings support further clinical trials of antibacterial chewing gum as an adjunct to existing cancer care or as a prophylactic approach to reduce pathogen burden and transmission. If validated in vivo, such products could offer a low-cost, accessible oral health intervention. Future studies should assess durability, safety, dosing frequency, and effects on cancer outcomes.
Reference
Daniell H et al. Ex vivo HNSCC clinical studies using saliva and antiviral or antibacterial chewing gums reveal reduction in carcinogenic microbes. Scientific Reports. 2026;DOI:10.1038/s41598-026-39062-w.
Featured image: Siphosethu/peopleimages.com on Adobe Stock
